NCT07105488 A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
| NCT ID | NCT07105488 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Bluefin Biomedicine, Inc. |
| Condition | Atopic Dermatitis (AD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 225 participants |
| Start Date | 2025-07-15 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 225 participants in total. It began in 2025-07-15 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Eligibility Criteria
Inclusion Criteria: * Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year. * Have moderate to severe disease not adequately controlled by topical treatments. * Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study. Exclusion Criteria: * Have certain infections or other immune conditions. * Recently used medications that could interfere with the study. * Are pregnant or breastfeeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07105488 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Atopic Dermatitis (AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07105488 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07105488 currently recruiting?
Yes, NCT07105488 is actively recruiting participants. Contact the research team at Reichelkraut@bluefinbiomed.com for enrollment information.
Where is the NCT07105488 trial being conducted?
This trial is being conducted at Phoenix, United States, Phoenix, United States, Encino, United States, Huntington Beach, United States and 11 additional locations.
Who is sponsoring the NCT07105488 clinical trial?
NCT07105488 is sponsored by Bluefin Biomedicine, Inc.. The trial plans to enroll 225 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.